PJ004
/ PEG-BIO Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 04, 2026
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
(clinicaltrials.gov)
- P1/2 | N=54 | Recruiting | Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
New P1/2 trial • Hematological Disorders • Hepatology • Thrombocytopenia
March 03, 2026
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. | Trial completion date: Oct 2025 ➔ Apr 2026 | Trial primary completion date: Oct 2025 ➔ Feb 2026
Trial completion date • Trial primary completion date • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
March 03, 2026
A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting ➔ Completed
Trial completion • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • Thrombocytopenia
November 06, 2024
Efficacy and Safety of Pegylated Peptide Agonist of Thrombopoietin Receptor (PN20) in Secondary Prevention of Chemotherapy-Induced Thrombocytopenias: A Multicenter, Single Arm, Phase Ib Trial
(ASH 2024)
- P1 | "This ongoing study is expected to provide a basis for the dosage selection of PN20 for CIT patients. In addition, a phase Ib clinical trial of PN20 for the treatment of primary immune thrombocytopenia (ITP) is also currently underway."
Clinical • P1 data • Biliary Cancer • Colorectal Cancer • Gastric Cancer • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Lung Cancer • Lymphoma • Oncology • Solid Tumor • Thrombocytopenia • Thrombocytopenic Purpura
March 17, 2025
Study of PN20 in Adult Patients with Primary Immune Thrombocytopenia (ITP)
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
1 to 5
Of
5
Go to page
1